Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 11:2020:8875554.
doi: 10.1155/2020/8875554. eCollection 2020.

Mesenchymal Stem Cells as Therapeutic Agents and Novel Carriers for the Delivery of Candidate Genes in Acute Kidney Injury

Yuxiang Liu  1 , Jingai Fang  2
Affiliations
Review

Mesenchymal Stem Cells as Therapeutic Agents and Novel Carriers for the Delivery of Candidate Genes in Acute Kidney Injury

Yuxiang Liu et al. Stem Cells Int. .

Abstract

Acute kidney injury (AKI) is a heterogeneous syndrome characterized by a dramatic increase in serum creatinine. Mild AKI may merely be confined to kidney damage and resolve within days; however, severe AKI commonly involves extrarenal organ dysfunction and is associated with high mortality. There is no specific pharmaceutical treatment currently available that can reverse the course of this disease. Notably, mesenchymal stem cells (MSCs) show great promise for the management of AKI by targeting multiple pathophysiological pathways to facilitate tubular epithelial cell repair. It has been well established that the unique characteristics of MSCs make them ideal vectors for gene therapy. Thus, genetic modification has been attempted to achieve improved therapeutic outcomes in the management of AKI by overexpressing trophic cytokines or facilitating MSC delivery to renal tissues. The present article provides a comprehensive review of genetic modification strategies targeted at optimizing the therapeutic potential of MSCs in AKI.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interest.

Figures

Figure 1
Figure 1
The mechanisms by which mesenchymal stem cells (MSCs) improve kidney injury.
See this image and copyright information in PMC

References

    1. Ronco C., Bellomo R., Kellum J. A. Acute kidney injury. The Lancet. 2019;394(10212):1949–1964. doi: 10.1016/S0140-6736(19)32563-2. - DOI - PubMed
    1. Kellum J. A., Prowle J. R. Paradigms of acute kidney injury in the intensive care setting. Nature Reviews. Nephrology. 2018;14(4):217–230. doi: 10.1038/nrneph.2017.184. - DOI - PubMed
    1. Liangos O., Wald R., O’Bell J. W., Price L., Pereira B. J., Jaber B. L. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clinical Journal of the American Society of Nephrology. 2006;1(1):43–51. - PubMed
    1. Agarwal A., Dong Z., Harris R., et al. Acute Dialysis Quality Initiative XIII Working Group. Cellular and molecular mechanisms of AKI. Journal of the American Society of Nephrology. 2016;27(5):1288–1299. doi: 10.1681/ASN.2015070740. - DOI - PMC - PubMed
    1. Rabb H., Griffin M. D., McKay D. B., et al. Acute Dialysis Quality Initiative Consensus XIII Work Group. Inflammation in AKI: current understanding, key questions, and knowledge gaps. Journal of the American Society of Nephrology. 2016;27(2):371–379. doi: 10.1681/ASN.2015030261. - DOI - PMC - PubMed

LinkOut - more resources